A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

~11 mi. (La Tronche, France, +31 more cities)

Centre Hospitalier Universitaire de Grenoble

TNFRSF8 Deficient Expression

Adult T-Cell Leukemia/Lymphoma, +8 more conditions

brentuximab vedotin, +3 more drugs

chemotherapy, +2 more types

Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

~11 mi. (La Tronche, France, +25 more cities)

CHU de Grenoble Hopital Nord ( Site 2027)

Melanoma

coxsackievirus A21, +1 more drug

immunotherapy

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

~12 mi. (Grenoble, France, +96 more cities)

Centre Hospitalier Universitaire de Grenoble

Diffuse Large B-Cell Lymphoma, +1 more condition

brentuximab vedotin, +2 more drugs

chemotherapy, +1 more type

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

~12 mi. (Grenoble, France, +87 more cities)

Hopital Albert Michallon

ALK Fusion

Non-Small Cell Lung Carcinoma

brigatinib

targeted therapy

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

~54 mi. (Sainte-Colombe, France, +41 more cities)

Clinique Trenel

Colorectal Adenocarcinoma

fluorouracil, +3 more drugs

chemotherapy, +2 more types

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~58 mi. (Valence, France, +137 more cities)

Centre Hospitalier de Valence-Service de Dermatologie ( Site 0377)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~62 mi. (Bron, France, +144 more cities)

Hopital Louis Pradel

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

~64 mi. (Lyon 08, France, +228 more cities)

Centre Leon Berard /ID# 205107

MET Expression

Non-Small Cell Lung Carcinoma

telisotuzumab vedotin

chemotherapy, +1 more type

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors

~64 mi. (Lyon 08, France, +29 more cities)

Centre Leon Berard /ID# 218515

ER Negative, +2 more biomarkers

Breast Adenocarcinoma, +1 more condition

ABBV-151, +1 more drug

immunotherapy, +1 more type

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior CML Therapies

~64 mi. (Lyon 08, France, +55 more cities)

Centre Léon Bérard

Chronic Myeloid Leukemia

vodobatinib

targeted therapy

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

~64 mi. (Lyon 08, France, +29 more cities)

Centre Leon Berard /ID# 163707

Cancer

chemotherapy, +1 more drug

chemotherapy

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

~64 mi. (Lyon 08, France, +24 more cities)

Centre Leon Berard /ID# 217910

ER Negative, +2 more biomarkers

Breast Adenocarcinoma, +2 more conditions

ABBV-368, +5 more drugs

chemotherapy, +1 more type